α-干扰素和苦参素可以减轻慢性乙型肝炎患者血清肝纤维化的程度  

Interferon-α and oxymatrine decrease the levels of serum fibrosis markers in patients with chronic hepatitis B

作　　者：杨清[1] 邓斌[1] 龚作炯[1] 

机构地区：[1]武汉大学人民医院感染科,湖北武汉430060

出　　处：《基础医学与临床》2005年第5期442-445,共4页Basic and Clinical Medicine

摘　　要：目的了解α-干扰素(IFN-α)、苦参素对慢性乙型肝炎患者血清肝纤维化指标的影响。方法84例患者随机分为干扰素、苦参素和联合治疗组,采用放射免疫法测定治疗前后血清透明质酸(HA)、层黏连蛋白(LN)、Ⅲ型前胶原(PCⅢ)、Ⅳ型胶原(Ⅳ-C)的变化。结果3组患者治疗后血清HA、LN、PCⅢ、Ⅳ-C水平较治疗前显著降低(P<0.05),联合治疗组降低幅度较干扰素组及苦参素组大(P<0.05)。治疗结束后血清乙型肝炎病毒E抗原(HBeAg)及乙型肝炎病毒DNA转阴情况3组间无明显差异。抗病毒治疗有效组与无效组治疗前血清HA、LN、PCⅢ、Ⅳ-C水平无显著差异,治疗后均明显降低(P<0.05),但有效组较无效组降低更加明显(P<0.01)。结论IFN-α与苦参素联合应用抗病毒效果与单一用药效果无差别,但有助于减轻慢性乙型肝炎纤维化程度,提高抗纤维化的效果。ObjectiveTo investigate the effects of Interferon-α(IFN-α) and oxymatrine on the levels of serum fibrosis markers in patients with chronic hepatitis B. MethodsEighty-four cases of chronic hepatitis B were randomly divided into IFN-α group, oxymatrine group and combined treatment group. We observed the changes of levels of serum HA?LN?PC?-C, and effects on HBeAg and HBV-DNA. The levels of serum HA?LN?PC?-C decreased significantly after treatment(P<0.05 or P<0.01).The decrease in combined treatment group was more obvious than that in IFN-α group and oxymatrine group(P<0.05 or P<0.01). ResultsThere was no difference among the groups concerning the rate of turning negative at the serum HBeAg and HBV-DNA.Before treatment, the levels of serum HA?LN?PC?-C were not difference between effective group and ineffective group on anti-virus. After treatment,they significantly decreased(P<0.05).But the levels of serum HA?LN?PC?-C in effective group were lower than those in ineffective group (P<0.01). ConclusionThe result indicated that of the combined treatment of IFN-α and oxymatrine were simitar with that of the single treatment of IFN-α or oxymatrine the anti-virus effects. But, the combined treatment seems more effective on the antifibrosis.

关 键 词：慢性乙型肝炎患者 Α-干扰素 苦参素 Ⅲ型前胶原(PCⅢ) 乙型肝炎病毒E抗原 血清肝纤维化指标 放射免疫法测定 IFN-α 血清透明质酸 血清HA 层黏连蛋白 DNA转阴 抗病毒治疗 抗病毒效果 纤维化程度 治疗前后 Ⅳ型胶原 抗纤维化 

分 类 号：R512.62[医药卫生—内科学] R512.6[医药卫生—临床医学]